Business Context and Reporting Period
On March 28, 2017, MaxLinear, Inc. filed a Form 8-K to announce the entry into a definitive merger agreement with Exar Corporation. The transaction involves MaxLinear acquiring all outstanding shares of Exar common stock through a cash tender offer followed by a merger.
Key Financial Metrics and Transaction Terms
- Purchase Price: $13.00 per share of Exar common stock in cash.
- Financing: MaxLinear secured a debt commitment letter for a secured term loan facility of up to $425,000,000 from JPMorgan Chase Bank, N.A. and Deutsche Bank AG New York Branch.
- Termination Fee: Exar is obligated to pay MaxLinear a termination fee of $24.8 million and reimburse expenses up to $3 million under certain termination scenarios.
- Support Agreements: Key stockholders of Exar, owning approximately 20% of outstanding shares, have agreed to tender their shares and vote against alternative proposals.
Material Changes and Conditions
The filing details the conditions required for the consummation of the offer, including:
- Tender of shares representing more than 50% of the sum of outstanding shares, vested options, and restricted stock units.
- Expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Completion of a 15-business-day marketing period for the debt financing.
- Absence of a Material Adverse Event.
The offer is scheduled to expire at midnight on the 20th business day following commencement, unless extended.
Outlook, Risks, and Management Commentary
Management anticipates strategic and financial synergies from the combination, though the filing includes standard forward-looking statements regarding the ability to integrate operations and retain key employees. Key risks identified include:
- Failure of Exar stockholders to tender sufficient shares.
- Failure to receive necessary regulatory approvals.
- Challenges and costs associated with closing, integrating, and restructuring the businesses.
- Potential changes in the recommendation of Exar's board of directors in response to superior proposals.
Regarding equity awards, vested options with exercise prices below the offer price will be cashed out. Unvested time-based awards will be assumed and converted into MaxLinear stock, while performance awards with periods ending in fiscal 2017 will vest based on criteria achievement, and those extending beyond will be assumed with performance deemed achieved at target.
Investor Verification Checklist
- Verify the final terms of the debt financing documentation, as the commitment letter terms are subject to change.
- Review the Tender Offer Statement on Schedule TO and the Solicitation/Recommendation Statement on Schedule 14D-9 for detailed offer mechanics.
- Monitor the tendering process to ensure the >50% ownership threshold is met.
- Assess the status of regulatory approvals under the Hart-Scott-Rodino Act.
- Confirm the treatment of specific employee equity awards if applicable to the investor's holdings or analysis.